Taylor Frigon Capital Management LLC Has $2.52 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Taylor Frigon Capital Management LLC cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,692 shares of the company’s stock after selling 336 shares during the period. IDEXX Laboratories makes up 1.3% of Taylor Frigon Capital Management LLC’s investment portfolio, making the stock its 25th biggest holding. Taylor Frigon Capital Management LLC’s holdings in IDEXX Laboratories were worth $2,517,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. MorganRosel Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the first quarter worth about $26,000. Opal Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after purchasing an additional 30 shares during the last quarter. WPG Advisers LLC acquired a new stake in IDEXX Laboratories in the 1st quarter worth approximately $37,000. Finally, Bank of Jackson Hole Trust boosted its position in IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after purchasing an additional 69 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Morgan Stanley lifted their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research note on Friday, August 15th. Finally, Leerink Partners boosted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $649.44.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the transaction, the executive vice president directly owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 in the last quarter. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Up 2.3%

Shares of IDXX opened at $632.22 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a 50-day simple moving average of $625.60 and a 200-day simple moving average of $529.00. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The firm has a market capitalization of $50.58 billion, a P/E ratio of 52.64, a P/E/G ratio of 4.09 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.